RT Journal Article SR Electronic T1 Protease inhibitors: Silver bullets for chronic hepatitis C infection? JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP 213 OP 222 DO 10.3949/ccjm.79a.11082 VO 79 IS 3 A1 Naim Alkhouri A1 Nizar N. Zein YR 2012 UL http://www.ccjm.org/content/79/3/213.abstract AB Recent trials evaluated the safety and efficacy of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), added to standard care with pegylated interferon and ribavirin, in patients with chronic hepatitis C virus (HCV) infection. These drugs open the door for triple therapy and other new therapies involving combinations of other direct-acting antiviral agents to become the new standard of care for this population.